| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
|
Lancet
|
2005
|
21.91
|
|
2
|
Effect of valsartan on the incidence of diabetes and cardiovascular events.
|
N Engl J Med
|
2010
|
5.46
|
|
3
|
Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants.
|
Nat Genet
|
2010
|
5.44
|
|
4
|
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
|
N Engl J Med
|
2010
|
4.38
|
|
5
|
Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies.
|
Diabetes
|
2007
|
3.25
|
|
6
|
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
|
Diabetes Care
|
2007
|
2.92
|
|
7
|
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
|
Diabetes
|
2004
|
2.74
|
|
8
|
Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
|
Basic Clin Pharmacol Toxicol
|
2004
|
1.73
|
|
9
|
Long-term AICAR administration and exercise prevents diabetes in ZDF rats.
|
Diabetes
|
2005
|
1.71
|
|
10
|
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects.
|
Am J Physiol Endocrinol Metab
|
2002
|
1.71
|
|
11
|
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome.
|
Diabetes
|
2002
|
1.69
|
|
12
|
Pulsatile insulin secretion: detection, regulation, and role in diabetes.
|
Diabetes
|
2002
|
1.68
|
|
13
|
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
|
Diabetes Care
|
2007
|
1.57
|
|
14
|
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
|
Diabetes Care
|
2004
|
1.56
|
|
15
|
Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes.
|
Diabetes
|
2008
|
1.55
|
|
16
|
Evaluation of iterative reconstruction (OSEM) versus filtered back-projection for the assessment of myocardial glucose uptake and myocardial perfusion using dynamic PET.
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.53
|
|
17
|
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
|
Diabetes
|
2002
|
1.46
|
|
18
|
[Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications].
|
Ugeskr Laeger
|
2003
|
1.39
|
|
19
|
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
|
Diabetes
|
2004
|
1.37
|
|
20
|
Impact of exercise training on insulin sensitivity, physical fitness, and muscle oxidative capacity in first-degree relatives of type 2 diabetic patients.
|
Am J Physiol Endocrinol Metab
|
2005
|
1.29
|
|
21
|
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.
|
Am J Physiol Heart Circ Physiol
|
2010
|
1.18
|
|
22
|
Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles.
|
J Appl Physiol (1985)
|
2002
|
1.16
|
|
23
|
Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men.
|
Diabetes
|
2010
|
1.07
|
|
24
|
Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population.
|
Diabetes Care
|
2007
|
1.06
|
|
25
|
Acute effects of ghrelin administration on glucose and lipid metabolism.
|
J Clin Endocrinol Metab
|
2007
|
1.05
|
|
26
|
Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
|
J Clin Endocrinol Metab
|
2003
|
1.00
|
|
27
|
Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration.
|
Basic Clin Pharmacol Toxicol
|
2008
|
0.99
|
|
28
|
Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients.
|
Eur J Endocrinol
|
2004
|
0.99
|
|
29
|
SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress.
|
PLoS One
|
2009
|
0.99
|
|
30
|
Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects.
|
J Clin Endocrinol Metab
|
2006
|
0.98
|
|
31
|
Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans.
|
Am J Physiol Endocrinol Metab
|
2007
|
0.98
|
|
32
|
Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure.
|
J Clin Endocrinol Metab
|
2007
|
0.98
|
|
33
|
Zinc-transporter genes in human visceral and subcutaneous adipocytes: lean versus obese.
|
Mol Cell Endocrinol
|
2006
|
0.96
|
|
34
|
Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis?
|
BMC Endocr Disord
|
2009
|
0.94
|
|
35
|
Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects.
|
Am J Physiol Endocrinol Metab
|
2003
|
0.94
|
|
36
|
Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans.
|
Obes Res
|
2002
|
0.93
|
|
37
|
Energy expenditure, insulin, and VLDL-triglyceride production in humans.
|
J Lipid Res
|
2006
|
0.93
|
|
38
|
Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training.
|
Metabolism
|
2006
|
0.92
|
|
39
|
Short-term changes in circulating insulin and free fatty acids affect Nt-pro-BNP levels in heart failure patients.
|
Int J Cardiol
|
2009
|
0.92
|
|
40
|
Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients.
|
Am J Physiol Endocrinol Metab
|
2003
|
0.92
|
|
41
|
The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects.
|
J Clin Endocrinol Metab
|
2008
|
0.91
|
|
42
|
Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects.
|
Diabetes
|
2008
|
0.91
|
|
43
|
Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model.
|
Anesthesiology
|
2004
|
0.89
|
|
44
|
Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion.
|
Am J Physiol Endocrinol Metab
|
2004
|
0.88
|
|
45
|
Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes.
|
Expert Rev Gastroenterol Hepatol
|
2008
|
0.88
|
|
46
|
Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
|
Am J Physiol Heart Circ Physiol
|
2010
|
0.88
|
|
47
|
Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.
|
Diabetes
|
2007
|
0.88
|
|
48
|
The effect of exercise, training, and inactivity on insulin sensitivity in diabetics and their relatives: what is new?
|
Appl Physiol Nutr Metab
|
2007
|
0.87
|
|
49
|
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.
|
Diabetes Metab Res Rev
|
2009
|
0.86
|
|
50
|
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
|
J Clin Endocrinol Metab
|
2010
|
0.86
|
|
51
|
Effects of fasting on physiologically pulsatile insulin release in healthy humans.
|
Diabetes
|
2002
|
0.85
|
|
52
|
The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
|
J Clin Endocrinol Metab
|
2007
|
0.85
|
|
53
|
The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
|
J Clin Endocrinol Metab
|
2004
|
0.85
|
|
54
|
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
|
Diabetes Care
|
2007
|
0.84
|
|
55
|
Impaired insulin action despite upregulation of proximal insulin signaling: novel insights into skeletal muscle insulin resistance in liver cirrhosis.
|
J Hepatol
|
2006
|
0.83
|
|
56
|
Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations.
|
Am J Physiol Gastrointest Liver Physiol
|
2005
|
0.82
|
|
57
|
Human insulin release processes measured by intraportal sampling.
|
Am J Physiol Endocrinol Metab
|
2002
|
0.81
|
|
58
|
Exercise and fasting activate growth hormone-dependent myocellular signal transducer and activator of transcription-5b phosphorylation and insulin-like growth factor-I messenger ribonucleic acid expression in humans.
|
J Clin Endocrinol Metab
|
2010
|
0.81
|
|
59
|
Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism.
|
J Clin Endocrinol Metab
|
2009
|
0.80
|
|
60
|
Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
|
Am J Physiol Endocrinol Metab
|
2004
|
0.80
|
|
61
|
Delayed β-cell response and glucose intolerance in young women with Turner syndrome.
|
BMC Endocr Disord
|
2011
|
0.80
|
|
62
|
High prevalence of impaired glucose homeostasis and myopathy in asymptomatic and oligosymptomatic 3243A>G mitochondrial DNA mutation-positive subjects.
|
J Clin Endocrinol Metab
|
2009
|
0.80
|
|
63
|
Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats.
|
Am J Physiol Endocrinol Metab
|
2010
|
0.80
|
|
64
|
Response of retinal arteriole diameter to increased blood pressure during acute hyperglycaemia.
|
Acta Ophthalmol Scand
|
2007
|
0.80
|
|
65
|
Microarray expression analysis in delayed cardioprotection: the effect of exercise, AICAR, or metformin and the possible role of AMP-activated protein kinase (AMPK).
|
Mol Cell Biochem
|
2011
|
0.79
|
|
66
|
Evaluation of the relationship between hyperinsulinaemia and myocardial ischaemia/reperfusion injury in a rat model of depression.
|
Clin Sci (Lond)
|
2009
|
0.77
|
|
67
|
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases myocardial glucose uptake during reperfusion and induces late pre-conditioning: potential role of AMP-activated protein kinase.
|
Basic Clin Pharmacol Toxicol
|
2009
|
0.77
|
|
68
|
Is metformin therapy for polycystic ovary syndrome safe during pregnancy?
|
Basic Clin Pharmacol Toxicol
|
2005
|
0.77
|
|
69
|
Muscle GLUT4 in cirrhosis.
|
J Hepatol
|
2007
|
0.77
|
|
70
|
Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
|
Clin Endocrinol (Oxf)
|
2008
|
0.77
|
|
71
|
Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease.
|
J Clin Endocrinol Metab
|
2006
|
0.77
|
|
72
|
Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans.
|
Metabolism
|
2012
|
0.76
|
|
73
|
New strategies in insulin treatment: analogues and noninvasive routes of administration.
|
Fundam Clin Pharmacol
|
2005
|
0.76
|
|
74
|
Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts.
|
Scand Cardiovasc J
|
2003
|
0.76
|
|
75
|
Acute hyperinsulinemia increases the contraction of retinal arterioles induced by elevated blood pressure.
|
Am J Physiol Heart Circ Physiol
|
2013
|
0.75
|
|
76
|
Insulin sensitivity and body composition in cirrhosis: changes after TIPS.
|
Am J Physiol Gastrointest Liver Physiol
|
2010
|
0.75
|
|
77
|
The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn?
|
J Clin Endocrinol Metab
|
2008
|
0.75
|
|
78
|
The circulating IGF system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects.
|
Clin Endocrinol (Oxf)
|
2003
|
0.75
|
|
79
|
Insulin-stimulated myocardial glucose uptake and the relation to perfusion and the nitric oxide system.
|
J Vasc Res
|
2004
|
0.75
|
|
80
|
[Coffee and diabetes--something to be really concerned about?].
|
Ugeskr Laeger
|
2002
|
0.75
|
|
81
|
Impact of type 2 diabetes on nitric oxide and adrenergic modulation of myocardial perfusion.
|
Diabetes
|
2007
|
0.75
|